MTSR
Metsera, Inc. Common StockMTSR
MTSR
About: Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
Employees: 98
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
51.89% more ownership
Funds ownership: 0% [Q4 2024] → 51.89% (+51.89%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$62
75%
upside
Avg. target
$64
79%
upside
High target
$65
84%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Cerena Chen | 84%upside $65 | Overweight Initiated | 20 Jun 2025 |
Guggenheim Evan Wang | 75%upside $62 | Buy Maintained | 10 Jun 2025 |
Financial journalist opinion
Based on 4 articles about MTSR published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress
MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025
Positive
Zacks Investment Research
2 days ago
Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Metsera Inc. (MTSR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
2 weeks ago
Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why
Metsera Inc. (MTSR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11 at 10:00 – 10:35 A.M. EDT. A live webcast and replay of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com.
Positive
Benzinga
1 month ago
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.
Positive
Reuters
1 month ago
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime.
Positive
Investors Business Daily
1 month ago
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch
Metsera stock surged Monday after the drugmaker unveiled "solid" results for a potential monthly shot to stoke weight loss.
Neutral
GlobeNewsWire
1 month ago
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.
Charts implemented using Lightweight Charts™